Patents Assigned to University of Zurich
-
Patent number: 10544213Abstract: Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced ?-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).Type: GrantFiled: March 12, 2015Date of Patent: January 28, 2020Assignees: Neurimmune Holding AG, University of ZurichInventors: Jan Grimm, Fabrice Heitz, Fabian Wirth, Tobias Welt
-
Publication number: 20200017577Abstract: Provided are novel TDP-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: February 25, 2019Publication date: January 16, 2020Applicants: Biogen International Neuroscience GmbH, University of ZürichInventors: Roger Nitsch, Christoph Hock, Maria Grazia Barenco Montrasio, Fabio Montrasio, Jan Grimm, Jean-Luc Baeriswyl, Paul Weinreb, Janaky Coomaraswamy, Omar Quintero-Monzon
-
Patent number: 10450365Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.Type: GrantFiled: August 16, 2017Date of Patent: October 22, 2019Assignees: Neurimmune Holding AG, University of ZurichInventors: Jan Grimm, Roland Martin, Benoit Combaluzier, Ivan Jelcic
-
Publication number: 20190263896Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.Type: ApplicationFiled: October 9, 2018Publication date: August 29, 2019Applicant: University of ZürichInventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
-
Publication number: 20190233506Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: September 12, 2018Publication date: August 1, 2019Applicants: Biogen International Neuroscience GmbH, University of ZürichInventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
-
Patent number: 10301381Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: March 7, 2018Date of Patent: May 28, 2019Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Publication number: 20190153082Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.Type: ApplicationFiled: December 19, 2018Publication date: May 23, 2019Applicant: University of ZurichInventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
-
Patent number: 10259866Abstract: Provided are TAR DNA-binding protein of 43 kDa (TDP-43)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: November 4, 2016Date of Patent: April 16, 2019Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Roger Nitsch, Christoph Hock, Maria Grazia Barenco Montrasio, Fabio Montrasio, Jan Grimm, Jean-Luc Baeriswyl, Paul Weinreb, Janaky Coomaraswamy, Omar Quintero-Monzon
-
Publication number: 20180371065Abstract: Provided are novel human ?-synuclein-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: January 9, 2018Publication date: December 27, 2018Applicants: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Publication number: 20180355027Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: March 7, 2018Publication date: December 13, 2018Applicants: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Patent number: 10131708Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.Type: GrantFiled: October 24, 2017Date of Patent: November 20, 2018Assignee: University of ZürichInventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
-
Patent number: 9975947Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: January 19, 2017Date of Patent: May 22, 2018Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Publication number: 20180134773Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.Type: ApplicationFiled: October 24, 2017Publication date: May 17, 2018Applicant: University of ZurichInventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
-
Patent number: 9896504Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: January 25, 2016Date of Patent: February 20, 2018Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Publication number: 20180002409Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: February 8, 2017Publication date: January 4, 2018Applicants: Biogen International Neuroscience GmbH, University of ZürichInventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
-
Publication number: 20170369592Abstract: Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.Type: ApplicationFiled: January 11, 2016Publication date: December 28, 2017Applicants: Mabimmune Diagostics AG, Neurimmune Holding AG, University of ZurichInventors: Chad BROKOPP, Jan GRIMM, Benoit COMBALUZIER, Mareike GOERANSON, Christine LOHMANN, Simon HOERSTRUP, Roger NITSCH
-
Patent number: 9828420Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.Type: GrantFiled: March 10, 2016Date of Patent: November 28, 2017Assignee: University of ZürichInventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
-
Patent number: 9828638Abstract: Described are methods and kits for identifying a subject at risk of, or having, a sensory neuropathy related disease, such as sensory neuropathies. In particular, the disclosure is based on the determination of mutations in the SPTLC2 gene causing sensory neuropathies.Type: GrantFiled: September 19, 2011Date of Patent: November 28, 2017Assignees: VIB VZW, Universiteit Antwerpen, University of Zurich, Medical University of GrazInventors: Annelies Rotthier, Vincent Timmerman, Michaela Auer-Grumbach, Thorsten Hornemann
-
Publication number: 20170283491Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.Type: ApplicationFiled: May 12, 2017Publication date: October 5, 2017Applicant: University of ZurichInventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
-
Patent number: 9771413Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.Type: GrantFiled: January 2, 2014Date of Patent: September 26, 2017Assignees: Neurimmune Holding AG, University of ZurichInventors: Jan Grimm, Roland Martin, Benoit Combaluzier, Ivan Jelcic